Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;74(1):483-490.
doi: 10.1002/hep.31697. Epub 2021 Jun 28.

Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma

David J Pinato  1 , Petros Fessas  1 , Gonzalo Sapisochin  2 , Thomas U Marron  3
Affiliations
Review

Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma

David J Pinato et al. Hepatology. 2021 Jul.
No abstract available

PubMed Disclaimer

References

    1. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894-1905. https://pubmed.ncbi.nlm.nih.gov/32402160/. Accessed June 26, 2020.
    1. Zhu AX, Finn RS, Ikeda M, Sung MW, Baron AD, Kudo M, et al. A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC). J Clin Oncol 2020;38(Suppl. 15):4519.
    1. Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015;16:1344-1354. https://pubmed.ncbi.nlm.nih.gov/26361969/. Accessed September 28, 2020.
    1. Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S, et al. Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 2016;44:924-938. https://pubmed.ncbi.nlm.nih.gov/27096321/. Accessed September 28, 2020.
    1. Sánchez-Paulete AR, Cueto FJ, Martínez-López M, Labiano S, Morales-Kastresana A, Rodríguez-Ruiz ME, et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov 2016;6:71-79. https://pubmed.ncbi.nlm.nih.gov/26493961/. Accessed September 28, 2020.

Publication types

MeSH terms

Substances